<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03678480</url>
  </required_header>
  <id_info>
    <org_study_id>HTD1801.PCT006</org_study_id>
    <nct_id>NCT03678480</nct_id>
  </id_info>
  <brief_title>A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighTide Biopharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighTide Biopharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, active-controlled, parallel-group study of HTD1801 in adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">November 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in gamma-glutamyl transferase (GGT)</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of patients whose GGT normalizes to &lt;50 units/liter</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in aspartate aminotransferase (AST)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in alanine aminotransferase (ALT)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in alkaline phosphatase (ALP)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total bilirubin</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in C-reactive protein (CRP)</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <condition>Cholangitis</condition>
  <condition>Cholangitis, Sclerosing</condition>
  <condition>Bile Duct Diseases</condition>
  <condition>Biliary Tract Diseases</condition>
  <condition>Digestive System Diseases</condition>
  <condition>Adolescent</condition>
  <arm_group>
    <arm_group_label>HTD1801 500 mg BID (twice daily), or 1000 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTD1801 tablets in double-blind capsules, 250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UDCA tablets in double-blind capsules, 250 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD1801</intervention_name>
    <description>HTD1801 capsules, 250mg</description>
    <arm_group_label>HTD1801 500 mg BID (twice daily), or 1000 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>UDCA capsules, 125mg</description>
    <arm_group_label>Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight ≥ 35 kg

          -  Previous cholangiographic evidence of PSC by magnetic resonance
             cholangiopancreatography (MRCP) or direct cholangiography or liver biopsy findings

          -  Serum GGT ≥ 2 × upper limit of normal (ULN)

          -  On a stable UDCA treatment regimen for ≥ 8 weeks

        Exclusion Criteria:

          -  Secondary sclerosing cholangitis

          -  Percutaneous or endoscopically-placed biliary drain or stent

          -  History of cholangiocarcinoma or clinical suspicion of new dominant stricture within 1
             year

          -  Ascending cholangitis requiring intravenous antibiotic therapy within 60 days prior to
             Screening

          -  Concomitant overlap syndrome with primary biliary cholangitis (PBC)

          -  Significant hepatic decompensation

          -  Alternative causes of chronic liver disease

          -  Hospitalization for colitis within 30 days prior to Screening

          -  Serum creatinine &gt; 1.2 x ULN

          -  Hemoglobin &lt; 10 g/dL

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cathryn Bennett, B.N., R.N., C.C.R.A.</last_name>
    <phone>1-760-809-3523</phone>
    <email>clinical.trials@hightidetx.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Biliary Tract Diseases</mesh_term>
    <mesh_term>Bile Duct Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

